- Whitening skin care productSkin-whitening cosmetic containing algae active extracts
-
The invention discloses a skin-whitening cosmetica whitening skin care product containing algae active extracts. The skin-whitening cosmetics iswhitening skin care product is prepared from the following raw materials in percentage by mass: 2 to 5 percent of hyaluronic acid, 0.5 to 1 percent of lecithin, 4 to 8 percent of glycerol, 1 to 5 percent of cetostearyl alcohol, 1 to 5.5 percent of glycerylstearate, 0.5 to 3 percent of polydimethylsiloxane, 0.5 to 1.5 percent of algal active extracts, 0.2 to 0.8 percent of whitening and anti-blackening agents, 2 to 6 percent of natural whitening grease, 0.5 to 1 percent of VC, 0.5 to 1 percent of VE, 0.1 to 0.35 percent of pH regulators, 1 to 5 percent of propanediol and the balance of deionized water. The raw material ingredients are scientifically proportioned; the activity of tyrosinase is inhibited internally in an inner aspect; the problem of melanin generation is fundamentally solved; in an outer aspectexternally, the active free radicalsare cleared through irideae extracts; the immunologic function of the skin is improved, so that the durable and continuous skin whitening effects can be achieved.
- -
-
Paragraph 0038; 0039
(2019/01/08)
-
- Development and evaluation of ST-1829 based on 5-benzylidene-2-phenylthiazolones as promising agent for anti-leukotriene therapy
-
Different inflammatory diseases and allergic reactions are mediated by leukotrienes, which arise from the oxygenation of arachidonic acid catalyzed by 5-lipoxygenase (5-LO). One promising approach for an effective anti-leukotriene therapy is the inhibition of this key enzyme. This study presents the synthesis and development of a potent and direct 5-LO inhibitor based on the well characterized 5-benzylidene-2-phenylthiazolone C06, whose further pharmacological investigation was precluded due to its low solubility. Through optimization of C06, evaluation of structure-activity relationships including profound assessment of the thiazolone core and consideration of the solubility, the 5-benzyl-2-phenyl-4-hydroxythiazoles represented by 46 (ST-1829, 5-(4-chlorobenzyl)-2-p-tolylthiazol-4-ol) were developed. Compound 46 showed an improved 5-LO inhibitory activity in cell-based (ICinf50/inf values 0.141/4M) and cell-free assays (ICinf50/inf values 0.03 1/4M) as well as a prominent enhanced solubility. Furthermore, it kept its promising inhibitory potency in the presence of blood serum, excluding excessive binding to serum proteins. These facts combined with the non-cytotoxic profile mark a major step towards an effective anti-inflammatory therapy.
- Lill, Andreas P.,R?dl, Carmen B.,Steinhilber, Dieter,Stark, Holger,Hofmann, Bettina
-
p. 503 - 523
(2014/12/11)
-